Aprea Therapeutics Secures $5.6M Private Placement at Premium, Reports First Partial Response for WEE1 Inhibitor

summarizeSummary

Aprea Therapeutics announced a $5.6 million private placement, significantly dilutive but priced at a premium to market, to fund operations and R&D, alongside reporting the first unconfirmed partial response in its Phase 1 WEE1 inhibitor study.

check_boxKey Events

• Secures $5.6 Million Private Placement

  Aprea Therapeutics entered into a securities purchase agreement to sell 6,288,857 shares (or pre-funded warrants) and accompanying common warrants to purchase an equal number of shares, for aggregate gross proceeds of approximately $5.6 million. The combined effective offering price is $0.89 per unit, representing a premium to the current market price.

• Reports First Unconfirmed Partial Response (uPR) for WEE1 Inhibitor

  The company announced the first unconfirmed partial response (uPR) in a patient with PPP2R1A-mutated uterine serous carcinoma (endometrial cancer) in its Phase 1 ACESOT-1051 dose-escalation study of WEE1 inhibitor APR-1051. This patient achieved a 50% reduction in target lesion size and a >90% decrease in CA-125 levels.

• Amends Prior Financing Agreement

  The company amended a Securities Purchase Agreement from December 8, 2025, with requisite holders, to allow for this new private placement, indicating a strategic move to secure additional capital.

• Financing to Fund Clinical Development

  The proceeds from the private placement are intended for general corporate purposes and research and development expenses, specifically to 'proactively backfill patients at key dose levels' in the ongoing APR-1051 study to accelerate dose optimization.

auto_awesomeAnalysis

This filing is critically important for Aprea Therapeutics, a nano-cap company that recently received a Nasdaq deficiency letter. The company announced a $5.6 million private placement, which, while highly dilutive (representing over 100% of its current market capitalization), is priced at a significant premium ($0.89 per unit vs. current stock price of $0.5805). This premium pricing, despite the massive dilution, suggests strong investor confidence in the company's prospects and provides crucial capital for continued operations and R&D. The financing is directly linked to advancing its clinical programs, specifically the WEE1 inhibitor APR-1051, which simultaneously reported its first unconfirmed partial response (uPR) in a Phase 1 study. This early clinical proof-of-concept for APR-1051 is a major positive catalyst for a clinical-stage biopharmaceutical company. The combination of securing vital funding (removing immediate going concern risk) and demonstrating promising clinical efficacy creates a significant positive shift in the company's outlook.